Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1

Fig. 1

Mature miR-1-3p expression levels in prostate cancer cell lines and tissues, and the prognostic value of miR-1-3p levels in patients with PCa. a Expression levels of miR-1-3p, (c) E2F5 and (e) PFTK-1 were examined by RT-qPCR in RWPE-1 cells and two PCa cell lines. GAPDH and U6 served as corresponding loading controls. Error bars represent the mean ± S.D. of three independent experiments (*P < 0.05, **P < 0.01 and ***P < 0.001 compared to RWPE-1 group). b Expression levels of mature miR-1-3p in 25 paired PCa and adjacent non-tumour tissues. Alteration of expression is shown as box plot presentations, with the y axis indicating miR-1-3p expression. The mean level of miR-1-3p expression in PCa tissues were significantly lower than that in non tumor tissues. (***P < 0.001, independent t test). d E2F5 and (f) PFTK-1 protein expression in primary prostate tissues was detected by Immunohistochemically staining assay. Scale bar: 50 μm. g 124 PCa patients from the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and (h) 402 PCa patients from the TCGA database. Left panel: X-tile plots automatically selected the cut-off point of miR-1-3p. Right panel: Kaplan–Meier analysis of survival and the COX proportional hazards model for the hazard ratio

Back to article page